<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981526</url>
  </required_header>
  <id_info>
    <org_study_id>2008-P-000790</org_study_id>
    <nct_id>NCT00981526</nct_id>
  </id_info>
  <brief_title>Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia</brief_title>
  <official_title>Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12-week, randomized, double-blinded, placebo-controlled trial of telmisartan 80
      mg/day as an adjunctive to clozapine or olanzapine therapy, in 70 schizophrenia subjects to
      examine telmisartan's effect on glucose metabolism, weight, food intake, resting energy
      expenditure, and body composition. In addition, the study will examine insulin's effects on
      psychopathology and cognition.

      Potential subjects will be identified by their clinicians at the Freedom Trail Clinic, or
      Massachusetts General Hospital. Approximately 70 subjects will be enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aims include:

      Primary Aims:

        1. Examine the efficacy of telmisartan added to regular doses of clozapine or olanzapine in
           improving insulin resistance.

        2. Examine the efficacy of telmisartan in reducing fasting triglycerides.

      Secondary Aims:

        1. Examine the effects of telmisartan on negative symptoms, positive symptoms, and
           cognitive function.

        2. Examine telmisartan's effects on lipids, body composition, and waist/hip ratio.

        3. Examine telmisartan's effects on inflammatory biomarkers including C-reactive protein
           (CRP) and interleukin 6 (IL-6).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Resistance</measure>
    <time_frame>12 weeks</time_frame>
    <description>Insulin resistance as estimated by homeostasis model of assessment of insulin resistance (HOMA-IR) at week 12 in both the experimental and placebo arm. Insulin resistance is a condition in which cells fail to respond to the normal action of the hormone in the body. The HOMA-IR is calculated using a subject's fasting plasma insulin and glucose levels. The higher the score, the higher the level of insulin resistance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>12 weeks</time_frame>
    <description>Fasting triglycerides assessed in both experimental and placebo arm at week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid Metabolism - LDL-cholesterol and HDL-cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>Lipid metabolism - fasting low density lipoprotein (LDL) and high density lipoprotein (HDL) are estimated in both experimental and placebo arms at 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychopathology - PANSS Total, PANSS - Negative Score, PANNS - Positive Score and SANS - Total Scores.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Positive and Negative Syndrome Scale (PANSS) and Scale for the Assessment of Negative Symptoms (SANS) were used to assess the positive and negative symptoms in experimental and placebo arms at 12 weeks. The PANSS total scale includes positive and negative subscales. For both subscales, the score ranges from 7-49 and total PANSS score ranges from 30-210. The total scale is a summation of all the subscales. The SANS score ranges from 0-100. For all scales, a greater score represents a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition: Waist to Hip Ratio</measure>
    <time_frame>12 weeks</time_frame>
    <description>Body composition as estimated by waist to hip ratio in both experimental and placebo arms at 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition: Percent Total Body Fat</measure>
    <time_frame>12 weeks</time_frame>
    <description>Body composition estimated by percent total body fat as measured by a dual energy absorptiometry (DXA) scan in both experimental and placebo arms at 12 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>A: Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(existing Clozapine or Olanzapine treatment) + (Telmisartan)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(existing Clozapine or Olanzapine treatment) + (Placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>Telmisartan 40mg/day for the first 2 weeks.
Telmisartan 80mg/day for the next 10 weeks.</description>
    <arm_group_label>A: Telmisartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (plus existing clozapine or olanzapine treatment) for 12 weeks.</description>
    <arm_group_label>B: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clozapine</intervention_name>
    <description>Clozapine (plus telmisartan or placebo) for 12 weeks.</description>
    <arm_group_label>A: Telmisartan</arm_group_label>
    <arm_group_label>B: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine (plus telmisartan or placebo) for 12 weeks.</description>
    <arm_group_label>A: Telmisartan</arm_group_label>
    <arm_group_label>B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-65 years

          2. Diagnosis of schizophrenia, any subtype or schizoaffective disorder, any subtype

          3. Treatment with clozapine or olanzapine for at least 6 months

          4. Stable dose of antipsychotic agent for at least one month

          5. Well establish compliance with out-patient medications

          6. Females subjects will be eligible to participate in the study if they are of
             non-childbearing potential or of child-bearing potential and willing to practice
             appropriate birth control methods (complete abstinence from sexual intercourse, female
             sterilization, sterilization of male partner, implants of levonorgestrel, injectable
             progestogen, oral contraceptives, intrauterine devices, or double barrier methods of
             contraception using spermicide with either a condom or diaphragm) during the study.

        Exclusion Criteria:

          1. Inability to provide informed consent

          2. Current substance abuse

          3. Psychiatrically unstable

          4. Significant medical illness including severe cardiovascular, hepatic, renal disease

          5. Current insulin treatment of diabetes

          6. History of immunosuppression

          7. Current or recent radiation or chemotherapy treatment for cancer

          8. Chronic use of steroids

          9. Pregnancy or breast feeding

         10. Use of diuretics, digoxin, warfarin because the possible drug-drug interaction of
             telmisartan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoduo Fan, MD, MPH, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMass Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <results_first_submitted>October 20, 2016</results_first_submitted>
  <results_first_submitted_qc>May 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2018</results_first_posted>
  <disposition_first_submitted>June 19, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>July 24, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 31, 2013</disposition_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Xiaoduo Fan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Cognition</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Antipsychotics</keyword>
  <keyword>Psychopathology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Clozapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 66 subjects were screened, 4 of which were screen fails. 62 subjects were then enrolled. Prior to randomization, 8 subjects withdrew consent. 54 subjects were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A: Telmisartan</title>
          <description>Telmisartan 80mg/day</description>
        </group>
        <group group_id="P2">
          <title>B: Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A: Telmisartan</title>
          <description>Telmisartan 80mg/day</description>
        </group>
        <group group_id="B2">
          <title>B: Placebo</title>
          <description>Placebo Group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.65" spread="12.14"/>
                    <measurement group_id="B2" value="44.68" spread="11.02"/>
                    <measurement group_id="B3" value="43.22" spread="11.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Resistance</title>
        <description>Insulin resistance as estimated by homeostasis model of assessment of insulin resistance (HOMA-IR) at week 12 in both the experimental and placebo arm. Insulin resistance is a condition in which cells fail to respond to the normal action of the hormone in the body. The HOMA-IR is calculated using a subject's fasting plasma insulin and glucose levels. The higher the score, the higher the level of insulin resistance.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A: Telmisartan</title>
            <description>Telmisartan 80mg/day</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo</title>
            <description>Placebo Group</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Resistance</title>
          <description>Insulin resistance as estimated by homeostasis model of assessment of insulin resistance (HOMA-IR) at week 12 in both the experimental and placebo arm. Insulin resistance is a condition in which cells fail to respond to the normal action of the hormone in the body. The HOMA-IR is calculated using a subject's fasting plasma insulin and glucose levels. The higher the score, the higher the level of insulin resistance.</description>
          <units>HOMA-IR scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9997" spread="1.4262"/>
                    <measurement group_id="O2" value="2.5824" spread="2.469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Triglycerides</title>
        <description>Fasting triglycerides assessed in both experimental and placebo arm at week 12.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A: Telmisartan</title>
            <description>Telmisartan 80mg/day</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides</title>
          <description>Fasting triglycerides assessed in both experimental and placebo arm at week 12.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.15" spread="156.02"/>
                    <measurement group_id="O2" value="176.72" spread="96.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipid Metabolism - LDL-cholesterol and HDL-cholesterol</title>
        <description>Lipid metabolism - fasting low density lipoprotein (LDL) and high density lipoprotein (HDL) are estimated in both experimental and placebo arms at 12 weeks.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A: Experimental</title>
            <description>Telmisartan 80mg/day</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Lipid Metabolism - LDL-cholesterol and HDL-cholesterol</title>
          <description>Lipid metabolism - fasting low density lipoprotein (LDL) and high density lipoprotein (HDL) are estimated in both experimental and placebo arms at 12 weeks.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL-cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" spread="35.71"/>
                    <measurement group_id="O2" value="107.85" spread="31.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.05" spread="9.59"/>
                    <measurement group_id="O2" value="43.18" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psychopathology - PANSS Total, PANSS - Negative Score, PANNS - Positive Score and SANS - Total Scores.</title>
        <description>The Positive and Negative Syndrome Scale (PANSS) and Scale for the Assessment of Negative Symptoms (SANS) were used to assess the positive and negative symptoms in experimental and placebo arms at 12 weeks. The PANSS total scale includes positive and negative subscales. For both subscales, the score ranges from 7-49 and total PANSS score ranges from 30-210. The total scale is a summation of all the subscales. The SANS score ranges from 0-100. For all scales, a greater score represents a worse outcome.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A: Experimental</title>
            <description>Telmisartan 80mg/day</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo</title>
            <description>Placebo Group</description>
          </group>
        </group_list>
        <measure>
          <title>Psychopathology - PANSS Total, PANSS - Negative Score, PANNS - Positive Score and SANS - Total Scores.</title>
          <description>The Positive and Negative Syndrome Scale (PANSS) and Scale for the Assessment of Negative Symptoms (SANS) were used to assess the positive and negative symptoms in experimental and placebo arms at 12 weeks. The PANSS total scale includes positive and negative subscales. For both subscales, the score ranges from 7-49 and total PANSS score ranges from 30-210. The total scale is a summation of all the subscales. The SANS score ranges from 0-100. For all scales, a greater score represents a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PANSS total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.41" spread="13.36"/>
                    <measurement group_id="O2" value="71.05" spread="20.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PANSS negative score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.55" spread="5.80"/>
                    <measurement group_id="O2" value="19.95" spread="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PANSS positive score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.50" spread="5.55"/>
                    <measurement group_id="O2" value="16.68" spread="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SANS total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.82" spread="11.27"/>
                    <measurement group_id="O2" value="29.28" spread="10.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Composition: Waist to Hip Ratio</title>
        <description>Body composition as estimated by waist to hip ratio in both experimental and placebo arms at 12 weeks.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A: Telmisartan</title>
            <description>Telmisartan 80mg/day</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo</title>
            <description>Placebo Group</description>
          </group>
        </group_list>
        <measure>
          <title>Body Composition: Waist to Hip Ratio</title>
          <description>Body composition as estimated by waist to hip ratio in both experimental and placebo arms at 12 weeks.</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="0.08"/>
                    <measurement group_id="O2" value="0.95" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Composition: Percent Total Body Fat</title>
        <description>Body composition estimated by percent total body fat as measured by a dual energy absorptiometry (DXA) scan in both experimental and placebo arms at 12 weeks.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A: Telmisartan</title>
            <description>Telmisartan 80mg/day</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Body Composition: Percent Total Body Fat</title>
          <description>Body composition estimated by percent total body fat as measured by a dual energy absorptiometry (DXA) scan in both experimental and placebo arms at 12 weeks.</description>
          <units>percentage of body fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" spread="9.88"/>
                    <measurement group_id="O2" value="31.28" spread="9.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>A: Experimental</title>
          <description>Telmisartan 80mg/day</description>
        </group>
        <group group_id="E2">
          <title>B: Placebo</title>
          <description>Placebo Group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Xiaoduo Fan</name_or_title>
      <organization>UMass Medical School</organization>
      <phone>508-856-3881</phone>
      <email>xiaoduo.fan@umassmed.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

